High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in<i>Enterobacteriaceae</i>Bloodstream Infections at a Major Cancer Center: Table 1. - Concepedia

Concepedia

Publication | Open Access

High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in<i>Enterobacteriaceae</i>Bloodstream Infections at a Major Cancer Center: Table 1.

DOI Full Paper Access

65

Citations

9

References

2016

Year

Samuel L Aitken, Jeffrey J. Tarrand, Lalitagauri M. Deshpande, Frank Tverdek, Anne Jones, Samuel A. Shelburne, Randall A. Prince, Micah M. Bhatti, Kenneth V. I. Rolston, Ronald N. Jones,

Clinical Infectious Diseases

Antibiotic ResistanceBacterial PathogensUnited StatesDrug ResistanceMedical MicrobiologyHigh RatesAntimicrobial TherapyInfection ControlAntimicrobial ResistanceTable 1Health SciencesCre BloodstreamBacterial ResistancePharmacologyClinical MicrobiologyAntimicrobial Resistance GeneAntimicrobial SusceptibilityAntibioticsNew Delhi Metallo-β-lactamaseMicrobiologyMajor Cancer CenterMedicineDiagnostic Microbiology

Abstract

Resistance to the novel β-lactam/β-lactamase inhibitor combination ceftazidime-avibactam (CAZ-AVI) among carbapenem-resistant Enterobacteriaceae (CRE) has infrequently been reported in the United States. We report unexpectedly high rates of resistance to CAZ-AVI in CRE bloodstream isolates at our institution associated with the nonoutbreak spread of New Delhi metallo-β-lactamase in diverse Enterobacteriaceae species.

References

	Year	Citations

Page 1